Evidence map›Paper›PMID 39060827›Full record

ArticleJournal of fluorescence2025

The Binding Mechanism Between Cyclodextrins and Anticancer Drug Noscapine: A Spectroscopic and Molecular Docking Study.

Arezu Hosseiny, Zahra Talebpour, Zahra Garkani-Nejad, Fereshteh Golestanifar

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Arezu HosseinyDepartment of Analytical Chemistry, Faculty of Chemistry, Alzahra University, Vanak, Tehran, Iran.
Zahra TalebpourDepartment of Analytical Chemistry, Faculty of Chemistry, Alzahra University, Vanak, Tehran, Iran. ztalebpour@alzahra.ac.ir.ORCID https://orcid.org/0000-0001-9016-9077
Zahra Garkani-NejadDepartment of Chemistry, Faculty of Science, Shahid Bahonar University of Kerman, Kerman, Iran.
Fereshteh GolestanifarDepartment of Chemistry, Faculty of Science, Shahid Bahonar University of Kerman, Kerman, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this paper the binding of noscapine (NOS) as an anticancer drug with poor bioavailability and low solubility with beta and methyl-beta cyclodextrins (β-CD and M-β-CD) as the biocompatible drug carriers were discussed using ultraviolet-visible, fluorescence and nuclear magnetic resonance spectroscopy, as well as molecular docking. The absorption of NOS changed when it was bound to both cyclodextrins, resulting in a hyperchromic shift. It formed a 1:1 stoichiometry inclusion complex with both cyclodextrins according to the Benesi-Hildebrand equation. The binding affinity was larger in NOS-M-β-CD (5.9 (± 0.66) × 10

Indexed as

Antineoplastic AgentsCyclodextrinsMolecular Docking SimulationNoscapineBinding SitesSpectrometry, FluorescenceThermodynamicsAntineoplastic AgentsCyclodextrinsNoscapineBenesi-hildebrand equationBeta-cyclodextrinInclusion complexMethyl-beta-cyclodextrinMolecular dockingNegative deviation stern-volmer

Identifiers

PMID39060827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.